Main Menu

Dr Alison Tree

Team Leader

The alt text
Dr Alison Tree is a clinical researcher investigating the benefits of profoundly hypofractionated radiotherapy in urological cancers. She is involved in several national and international trials of innovative radiotherapy strategies, and has a particular interest in prostate cancer. Team: Uro-oncology Clinical Trials ORCID 0000-0002-5033-424X

Biography

Dr Alison Tree was appointed as a consultant clinical oncologist at The Royal Marsden NHS Foundation Trust in 2014, specialising in urological malignancies. Her MD thesis was on stereotactic body radiotherapy (SBRT) techniques for prostate and oligometastatic cancer.

Her current research interests focus on technical radiotherapy developments in prostate cancer, aiming to make radiotherapy more effective and reduce side effects. Dr Tree leads the Prostate Group in the International MR Linac consortium. She is currently leading trials in MR-guided prostate radiotherapy (the PRISM trial), boosting dominant intra-prostatic lesions (the DELINEATE trial) and ablating oligoprogressing metastases in advanced prostate cancer (the TRAP trial). She will soon be starting the HERMES trial which is testing whether prostate cancer can be cured in just 2 fractions.